Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.1552W HIGH $30.56
Volume
64.64 K
Value Traded
1.34 M
Short % Float
8.8%
-1.2%Week
-10.47%1 Month
+9.33%3 Month
+18.65%6 Month
-17.47%5 Year
-17.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
823.49 M
EPS (TTM)
-11.50
P/E Ratio
-
Ent. Value
589.30 M
Total Shares
33.43 M
Float Shares
13.97 M
Insiders
58.24%
Institutions
40.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SGP Catalyst Timeline
Dated clinical, regulatory and corporate events for SpyGlass Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SpyGlass Pharma, Inc.
11Total events
4Upcoming
1Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 5
▲AcquiredCorporate
SpyGlass Pharma acquires 100% of Advanced Vision Science, Inc. (AVS) for ~$13 million in cash
▲Other Regulator MilestoneEx-US Regulatory
CPT Category III code approved
glaucoma and ocular hypertensionsource ↗
Past FDA Catalysts and PDUFA Decisions
How SGP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$24M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 67%
Micro Cap(rank 441 of 658)
Percentile Rank
SpyGlass Pharma, Inc. faces pipeline headwinds (31/100), with $59M risk-adjusted pipeline value, led by BIM-DRS in Glaucoma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIM-DRS Small moleculeNCT07641296 | Glaucoma | Phase 1 | NOT YET_RECRUITING | 24 | Mar 31, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every SGP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BIM-IOL System | open-angle glaucoma (OAG) or ocular hypertension (OHT) | Phase 1/2 | 2026-05-14 | In the Phase 1/2 trial of the BIM-IOL System, 98% of participants were free from topical IOP-lowering medications, achieving a mean IOP reduction of 34% from baseline at a dose of 78-mcg, with all patients reaching a best-corrected distance visual acuity of 20/32 or better.Read More | SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.Director, 10% Owner | Buy | 3,441,966 5,966,439 held | $16.00 | 02/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SGP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 10.4 % (-4.6 %) | 164.55 M | 7.39 M |
SGP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SGP ranks across every disease it competes in
Competitive Position is a premium feature
See how SGP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSGP News
SGPSpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
SpyGlass Pharma has acquired Advanced Vision Science, Inc. (AVS) for approximately $13 million, enhancing its manufacturing capabilities for intraocular lenses (IOLs). This acquisition will support the production of its BIM-IOL System, currently in Phase 3 trials, and allow the company to expand its lens portfolio. AVS will continue to supply IOLs to Santen and other global companies.
Read more →SGP▲ +5.3%on this news
SpyGlass Pharma to Participate in Upcoming Investor Conferences
SpyGlass Pharma, a late-stage biopharmaceutical company, announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and Citi's Biopharma Back to School Conference. The company's focus is on developing innovative drug delivery solutions for chronic eye conditions. Live webcasts of key presentations will be available on their website.
Read more →SGPSpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
SpyGlass Pharma has officially opened its new 33,000-square-foot headquarters in Irvine, California, marking a significant milestone in its growth. The company aims to launch its first product and expand its research and development capabilities. Following a successful IPO in February 2026, SpyGlass has increased its workforce by 33%, reflecting its commitment to innovation in ophthalmic care.
Read more →SGPSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma reported its Q2 2026 financial results, highlighting that enrollment in the Phase 3 trials of the BIM-IOL System is on track for completion in 2027. The company also plans to initiate a first-in-human trial for the BIM-DRS in the second half of 2026. With $234.2 million in cash reserves, SpyGlass is well-positioned to fund operations through 2028, despite reporting a net loss of $19.9 million for the quarter.
Read more →SGPSpyGlass Pharma Appoints Shannon Treviño as General Counsel
SpyGlass Pharma has appointed Shannon Treviño as General Counsel, bringing significant legal expertise to the company. Treviño's background includes leadership roles in corporate law and successful navigation of major acquisitions. Her appointment coincides with the advancement of SpyGlass's BIM-IOL System through Phase 3 clinical trials, aiming for potential commercialization.
Read more →SGPSpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
SpyGlass Pharma has appointed Mike Pinder as Vice President of Marketing, leveraging his extensive experience in ophthalmology. Pinder will lead marketing efforts as the company advances its BIM-IOL System through Phase 3 clinical trials. His background includes successful brand launches, which are expected to support the commercialization of the innovative drug delivery technology.
Read more →SGPSpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
SpyGlass Pharma announced the approval of a new add-on Category III CPT code for its BIM-IOL System, which combines glaucoma and cataract treatment. This code aims to enhance reimbursement pathways, potentially increasing patient access to this innovative technology. The BIM-IOL System is currently undergoing Phase 3 clinical trials, with enrollment expected to complete in 2027.
Read more →SGPSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma reported its Q1 2026 financial results, highlighting positive topline data from its Phase 1/2 trial of the BIM-IOL System, which showed significant intraocular pressure reduction. The company is on track to complete enrollment in its Phase 3 trials by 2027 and has a strong cash position to fund operations through 2028. The CEO emphasized the potential benefits of the BIM-IOL System for glaucoma patients.
Read more →SGP▼ -10.3%on this news
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
SpyGlass Pharma reported its fourth quarter and full year 2025 earnings, highlighting the initiation of two Phase 3 trials for its BIM-IOL System. The company achieved positive results in its Phase 1/2 trial, showing significant intraocular pressure reduction. Despite a net loss of $39.9 million, SpyGlass is well-funded following its IPO, which positions it for future growth.
Read more →SGPSpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
SpyGlass Pharma announced positive results from its Phase 1/2 trial of the BIM-IOL System, showing significant reductions in intraocular pressure (IOP) and improved visual acuity in patients with open-angle glaucoma or ocular hypertension. The trial demonstrated that 97% of patients were free from topical IOP-lowering medications after 12 months. Safety results were comparable to standard cataract surgery, indicating the system's potential for long-term treatment adherence.
Read more →SGPSpyGlass Pharma Announces Positive Topline 12-Month Phase 1 2 Trial Results for Its Innovative BIM-IOL System
SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial for the BIM-IOL System, indicating it effectively reduces elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The trial included 104 patients, and results showed 97% were off all topical IOP-lowering medications, with 100% reaching at least 20/32 vision. Safety results were comparable to traditional cataract surgery, with no serious adverse events reported. The company is focused on advancing further trials towards potential commercial approval.
Read more →SGPSpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
SpyGlass Pharma, a late-stage biopharmaceutical company, will host one-on-one meetings at the Jefferies Biotech on the Beach Summit in Miami Beach on March 11, 2026. The company aims to improve treatment for chronic eye conditions through its innovative drug delivery platform, which utilizes approved medicines. Founded in 2019, SpyGlass Pharma focuses on durable solutions for eye care.
Read more →SGP▲ +6.3%on this news
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
SpyGlass Pharma has announced the successful closing of its initial public offering, raising $172.5 million by offering 10,781,250 shares at $16.00 each. This includes the full exercise of the underwriters' option to purchase additional shares. The company's stock began trading on Nasdaq under the ticker SGP on February 6, 2026.
Read more →SGPSpyGlass Pharma Announces Pricing of Initial Public Offering
SpyGlass Pharma has announced the pricing of its initial public offering, offering 9,375,000 shares at $16.00 each, aiming to raise around $150 million. The IPO is set to close on February 9, 2026, and the shares will begin trading on the Nasdaq Global Select Market on February 6, 2026. The company focuses on innovative treatments for chronic eye conditions.
Read more →About SpyGlass Pharma, Inc.
Headquarters15326 ALTON PARKWAY, IRVINE, CA, 92618
BIOPHARMAWATCH ELITE PLUS
Trade the next SGP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime